Recommendation for caution with irinotecan, fluorouracil, leucovorin for colorectal cancer

被引：0
|
作者：
Klautke, G
Fietkau, R
机构：
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2002年 / 178卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：163 / 164
页数：2
相关论文
共 50 条
  • [21] Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer
    Falcone, A
    Masi, G
    Allegrini, G
    Danesi, R
    Pfanner, E
    Brunetti, IM
    Di Paolo, A
    Cupini, S
    Del Tacca, M
    Conte, P
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) : 4006 - 4014
  • [22] Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer
    Chong, Dawn Q.
    Manalo, Mary
    Imperial, Marlowe
    Teo, Patrick
    Yong, Grace
    Ng, Matthew
    Tan, Iain B. H.
    Choo, Su Pin
    Chua, Clarinda
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (03) : 275 - 283
  • [23] Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Meyerhardt, Jeffrey A.
    Clark, Jeffrey W.
    Supko, Jeffrey G.
    Eder, Joseph P.
    Ogino, Shuji
    Stewart, Clinton F.
    D'Amato, Ferdinando
    Dancey, Janet
    Enzinger, Peter C.
    Zhu, Andrew X.
    Ryan, David P.
    Earle, Craig C.
    Mayer, Robert J.
    Michelini, Ann
    Kinsella, Kate
    Fuchs, Charles S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 661 - 670
  • [24] Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A. Meyerhardt
    Jeffrey W. Clark
    Jeffrey G. Supko
    Joseph P. Eder
    Shuji Ogino
    Clinton F. Stewart
    Ferdinando D’Amato
    Janet Dancey
    Peter C. Enzinger
    Andrew X. Zhu
    David P. Ryan
    Craig C. Earle
    Robert J. Mayer
    Ann Michelini
    Kate Kinsella
    Charles S. Fuchs
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 661 - 670
  • [25] Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
    Berlin, Jordan
    Posey, James
    Tchekmedyian, Simon
    Hu, Eddie
    Chan, David
    Malik, Imtiaz
    Yang, Liqiang
    Amado, Rafael G.
    Hecht, J. Randolph
    CLINICAL COLORECTAL CANCER, 2007, 6 (06) : 427 - 432
  • [26] Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients
    François Ghiringhelli
    Julie Vincent
    Françoise Beltjens
    Leila Bengrine
    Sylvain Ladoire
    Investigational New Drugs, 2015, 33 : 1263 - 1266
  • [27] Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer
    Kono, T
    Ebisawa, Y
    Tomita, I
    Chisato, N
    Kamiya, K
    Asama, T
    Ayabe, T
    Ashida, T
    Kohgo, Y
    Kasai, S
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (02) : 224 - 227
  • [28] UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
    R Petrioli
    M Sabatino
    A I Fiaschi
    S Marsili
    D Pozzessere
    S Messinese
    P Correale
    S Civitelli
    G Tanzini
    F Tani
    A De Martino
    G Marzocca
    M Lorenzi
    G Giorgi
    G Francini
    British Journal of Cancer, 2004, 90 : 306 - 309
  • [29] UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
    Alliot, C
    BRITISH JOURNAL OF CANCER, 2004, 91 (03) : 599 - 600
  • [30] UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
    C Alliot
    British Journal of Cancer, 2004, 91 : 599 - 600
12345